Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Phase 2
40
about 7.8 years
18+
1 site in IL
About this study
This trial is testing a new treatment with four drugs (decitabine, selinexor, carboplatin, and paclitaxel) for ovarian cancer patients whose cancer has returned. The goal is to learn about the side effects and effectiveness of this combination therapy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Carboplatin
- 2.Take Decitabine
- 3.Take Paclitaxel
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
carboplatin, decitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules), selinexor
injection, intravenous, oral (Oral Tablet)
Primary: 40 participants evaluated for safety with treatment-related adverse events and grading using CTCAE 4.3.
Secondary: 40 participants evaluated for tolerability with treatment-related adverse events and grading using CTCAE 4.3., 40 participants evaluated to determine the clinical efficacy of this novel regimen in both platinum sensitive and resistant recurrent disease as measured by response rates. Response rates (partial response [PR] and complete response [CR])
Oncology